Dapagliflozin · larger labeled portfolio than Bumetanide
SPL labels Dapagliflozin + Bumetanide as minor; Dapagliflozin 13 / Bumetanide 2 in that band.
Mechanism on file: These medications do not significantly change how the other is processed by your body.
FDA SPL severity: Minor
Dapagliflozin + Bumetanide · SPL mechanism field
These medications do not significantly change how the other is processed by your body.
Minor band excerpt · Dapagliflozin with Bumetanide
No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once daily for 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12% [↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7% [↓22%, ↑11%] ↓22% [↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of...
Dapagliflozin · 13 SPL pairs (broader portfolio than Bumetanide)
- Digoxin minor
- Glimepiride minor
- Hydrochlorothiazide minor
- Lithium minor
FDA Drug Labels (SPL) via openFDA. Registry display only. Not medical advice.
Read our methodology - how this data is sourced, computed, and verified.